Citadel Advisors’s iRadimed IRMD Stock Holding History

Citadel Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,800	Closed	-$558K	–	14270
2026 Q1	$558K	Buy	+5,800	New	+$580K	﹤0.01%	9038
2025 Q4	–	Sell	-5,300	Closed	-$377K	–	13353
2025 Q3	$377K	Buy	+5,300	New	+$353K	﹤0.01%	9814
2025 Q1	–	Sell	-900	Closed	-$49.5K	–	15010
2024 Q4	$49.5K	Buy	+900	New	+$47.4K	﹤0.01%	12402
2024 Q3	–	Sell	-100	Closed	-$4.39K	–	14717
2024 Q2	$4.39K	Sell	100 -1,900	-95%	-$80.8K	﹤0.01%	13489
2024 Q1	$88K	Buy	2,000 +400	+25%	+$17.7K	﹤0.01%	11525
2023 Q4	$76K	Buy	+1,600	New	+$67.3K	﹤0.01%	11284

Other funds holding IRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's IRMD Position: Q2 2026 in Review

Citadel Advisors sold out of iRadimed (IRMD) in Q2 2026, closing a stake of 32,504 shares — an estimated $2.96M sold.

Citadel Advisors first reported a position in IRMD in Q1 2020 and held it in 17 quarters. The position peaked at $5.42M in Q4 2025. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

Citadel Advisors reported no remaining iRadimed position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 32,504 iRadimed shares in Q2 2026, an estimated $2.96M.
Citadel Advisors first reported a position in iRadimed in Q1 2020 and held it in 17 quarters.
Citadel Advisors's iRadimed position peaked at $5.42M in Q4 2025.
214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.